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Abstract Purpose: Neutrophil
gelatinase-associated lipocalin
(NGAL) is a useful marker for acute
kidney injury (AKI), particularly
when the timing of renal insult is
known. However, its performance in
an adult critical care setting has not
been well described. We performed
this study to estimate the diagnostic
accuracy of plasma NGAL for early
detection of AKI and need for renal
replacement therapy (RRT) in an
adult intensive care unit (ICU).
Methods: We enrolled 307 consec-
utive adult patients admitted to a
general medical-surgical ICU; 301
were included in the ﬁnal analysis.
Serial blood samples were analyzed
for plasma NGAL using a standard-
ized clinical platform. The primary
outcome was AKI, deﬁned as an
increase in creatinine of at least 50%
from baseline or a reduction in urine
output to\0.5 ml/kg/h for[6h .
Results: Of 301 patients, 133 (44%)
had AKI during their ICU stay.
Plasma NGAL was a good diagnostic
marker for AKI development within
the next 48 h (area under ROC 0.78,
95% CI 0.65–0.90), and for RRT use
(area under ROC 0.82, 95% CI 0.70–
0.95). Peak plasma NGAL concen-
trations increased with worsening
AKI severity (R = 0.554,
P\0.001). Conclusions: Plasma
NGAL is a useful early marker for
AKI in a heterogeneous adult ICU
population, in which the timing of
renal insult is largely unknown. It
allows the diagnosis of AKI up to
48 h prior to a clinical diagnosis
based on AKI consensus deﬁnitions.
Additionally, it predicts need for RRT
and correlates with AKI severity.
Early identiﬁcation of high risk
patients may allow potentially bene-
ﬁcial therapies to be initiated early in
the disease process before irreversible
injury occurs.
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Acute kidney injury (AKI) is a common and serious
process that occurs in a wide variety of clinical settings.
Lack of early AKI biomarkers has impeded timely
interventions to ameliorate the downstream effects of AKI
and has hindered further clinical investigation of therapies
that are effective in animal studies.
Neutrophil gelatinase-associated lipocalin (NGAL) is
a promising biomarker for early detection of AKI [1].
Several studies have shown serum and urine NGAL to be
useful early markers for AKI, particularly when the tim-
ing of the renal insult is known, such as post-cardiac
surgery and radiocontrast exposure [2, 3]. However, its
performance in a more general intensive care unit (ICU)
setting has not been as well described. Urine NGAL was
found to be a useful early marker for development of AKI
in pediatric ICU patients (AuROC 0.78) [4], whereas
serum NGAL was a highly sensitive but nonspeciﬁc
predictor of AKI in critically ill children with septic shock
(AuROC 0.68) [5]. We hypothesized that plasma NGAL
would also be an early biomarker of AKI in an unselected
population of critically ill adults.
The main objective of the study was to estimate the
diagnostic accuracy of plasma NGAL (pNGAL) in an
adult general ICU for the early detection of AKI. Addi-
tional objectives were to evaluate pNGAL as a biomarker
for renal replacement therapy (RRT) use and mortality in
the ICU, as well as to explore the relationship between
pNGAL, AKI severity and overall severity of illness.
Concise methods
Study design and setting
This was a prospective observational study of consecutive
adult patients admitted to a general ICU from January to
July 2007. Patients were enrolled within 24 h of ICU
admission; informed consent was obtained from the
patient surrogate. Detailed methods are described in ESM
File 1.
Clinical and laboratory data collection
Multiple data elements were collected for each patient
and included demographics, co-morbidities, admission
diagnosis, severity of illness scores, RRT provision and
ICU mortality. Clinical charts were reviewed for a history
of exposure to potential nephrotoxins and use of diuretics
in the ICU.
Laboratory data were measured daily as part of routine
patient care. Blood samples for NGAL were collected
daily from ICU admission for up to 4 days. Reasons for
not collecting blood samples for NGAL for all 4 days
included death, ICU discharge and ongoing RRT.
Deﬁnition of acute kidney injury
AKI was deﬁned using the creatinine and urine output
criteria of the RIFLE (Risk-Injury-Failure-Loss-Endstage
renal disease) classiﬁcation [6]. Baseline renal function
was deﬁned as the lowest known SCr value during the
preceding 3 months. For patients without known prior
SCr, the baseline serum creatinine was estimated by
solving the MDRD equation [6, 7].
Patients were classiﬁed daily using the RIFLE criteria.
RIFLE-initial refers to their RIFLE class on the ﬁrst day
of AKI. RIFLE-max refers to the worst RIFLE class
reached by a patient during his ICU stay. For AKI
patients, renal status at ICU discharge was deﬁned as
follows: Complete recovery if discharge SCr was\150%
of baseline; partial recovery if discharge SCr was 150–
199% of baseline; non-recovery if discharge SCr was
C200% of baseline or still receiving RRT.
Sampling and measurement of NGAL
Blood samples for NGAL were collected daily, and
samples were processed within 1 h from time of collec-
tion. We centrifuged samples at 3,5009g for 10 min and
stored the supernatant in equal volumes at -80C until
measurement. Plasma NGAL (pNGAL) was measured
using the Triage NGAL Test (Biosite Inc, San Diego,
CA), a point-of-care, ﬂuorescence-detected immunoassay.
We measured pNGAL in 873 blood samples (median 3
samples/patient). Laboratory investigators were blinded to
sample sources and clinical information until the end of
the study. For comparative purposes, pNGAL was mea-
sured in banked anti-coagulated plasma of apparently
healthy donors (n = 120).
Statistical analysis
Continuous variables are expressed as mean ± standard
deviation or median (interquartile range) and compared
betweenanytwogroupsusingt-testortheMann–WhitneyU
test, and among three or more groups using analysis of var-
iance (general linear models with adjustment for multiple
comparisons)ortheKruskal–Wallistest,whereappropriate.
Categorical variables are expressed as proportions and
compared with the chi-square test or Fisher’s exact test.
Diagnostic characteristics of pNGAL were evaluated
with receiver-operating characteristic (ROC) curves. The
primary outcome of interest was prediction of AKI. Based
on prior studies [4, 8], for our primary analysis we deﬁned
an event as AKI occurring within 48 h of ﬁrst pNGAL
445measurement. Secondary outcomes included RRT use,
ICU mortality, and their composite endpoint.
After seeing the relationship between pNGAL and
these scores, we also performed a post hoc covariate
analysis using multiple logistic regression to determine
the independent predictive ability of the ﬁrst pNGAL for
AKI within 48 h. The following covariates were consid-
ered: age, APACHE, SAPS and SOFA scores. For all
analyses, two-tailed P values \0.05 were considered
signiﬁcant. Statistical analyses were conducted using
SPSS 15 (SPSS Inc., Chicago, IL) and MATLAB 7.5.0
(The MathWorks, Inc., Natick, MA).
Results
Patient demographics
We enrolled 307 consecutive incident patients to an adult
medical-surgicalICU.Weexcluded5patientswithendstage
renal disease on chronic RRT and 1 patient for uninter-
pretable NGAL result, leaving 301 patients for analysis.
Patient characteristics are shown in Table 1. Two hundred
twenty patients (73%) had an eGFR\90 ml/min/1.73 m
2,
ofwhom20(6.6%)hadaneGFR\60 ml/min/1.73 m
2.T h e
mostcommondiagnosticcategoriesforICUadmissionwere
Neurologic, Respiratory, Cardiovascular, Trauma and
Gastrointestinal,accountingfor89%ofadmissions.Median
ICU length of stay was 7 days (IQR 3, 13). Crude ICU and
hospital mortalities were 17.3 and 25.5%, respectively,
and 58 (19.3%) patients met the composite RRT or ICU
death endpoint.
Acute kidney injury
Of 301 patients, 133 (44%) had AKI during their ICU
stay; 90 patients had AKI within 24 h of ICU admission,
while 43 developed it later during their ICU stay (median
3rd day, IQR 2–5) (see ESM File 1, ESM Table 1).
RIFLE-initial class was Risk in 92 patients (30.6%),
Table 1 Characteristics of the cohort by presence or absence of acute kidney injury (AKI)
All Non-AKI AKI P
N 301 168 133
Male sex (%) 207 (68.8) 113 (67.3) 94 (70.7) 0.53
Age (years) 64 (45,74) 58 (37, 70.5) 69 (61, 76.5) \0.001
Body weight (kg) 76.5 ± 12.3 75.6 ± 13.1 77.7 ± 11.2 0.16
Baseline creatinine (mg/dl) 0.9 (0.8, 1.0) 0.9 (0.8, 1.0) 1.0 (0.8, 1.0) 0.035
Diabetes (%) 47 (15.6) 16 (9.5) 31 (23.3) 0.001
Chronic kidney disease (%) 20 (6.6) 8 (4.8) 12 (9.0) 0.16
Patient type
Medical (%) 164 (54.6) 85 (50.6) 79 (59.4) 0.13
Elective surgery (%) 25 (8.3) 14 (8.3) 11 (8.3) 1.00
Emergency surgery (%) 112 (37.1) 69 (41.1) 43 (32.3) 0.15
Admission diagnosis
Neurologic (%) 90 (29.9) 66 (39.3) 24 (18) \0.001
Respiratory (%) 57 (18.9) 24 (14.3) 33 (24.8) 0.026
Cardiovascular (%) 51 (16.9) 23 (13.7) 28 (21.1) 0.12
Trauma (%) 49 (16.3) 31 (18.5) 18 (13.5) 0.27
Gastrointestinal (%) 22 (7.3) 10 (6.0) 12 (9.0) 0.374
ICU admission
SAPS II 41 ± 15 38 ± 15 45 ± 14 \0.001
APACHE II 18 ± 71 6 ± 72 0 ± 7 \0.001
SOFA 5 (5, 7) 5 (4, 6) 5 (5, 8) \0.001
Creatinine (mg/dl) 1.0 (0.8, 1.4) 0.9 (0.8, 1.1) 1.3 (1.0, 2.0) \0.001
Plasma NGAL (ng/ml) 117.0 (68.2, 213.8) 82.0 (49.7, 134.1) 185 (95.4, 403.5) \0.001
Potential nephrotoxins (%) 38 (12.6) 15 (8.9) 23 (17.3) 0.036
Use of vasopressors (%) 102 (33.9) 35 (20.8) 67 (50.4) \0.001
ICU course
Diuretics (%) 157 (52.2) 65 (38.7) 92 (69.2) \0.001
Sepsis (%) 115 (38.2) 49 (29.2) 66 (49.6) \0.001
Outcome
ICU mortality (%) 52 (17.3) 15 (8.9) 37 (27.8) \0.001
RRT or ICU mortality (%) 58 (19.3) 15 (8.9) 43 (32.3) \0.001
ICU length of stay (days) 7 (3, 13) 5 (3, 10) 9 (5, 15) \0.001
ICU LOS: survivors (days) 7 (3, 13) 6 (3,10.5) 9 (5,15.8) \0.001
ICU LOS: nonsurvivors (days) 7 (4, 13) 5 (2,7) 9 (4,16) 0.019
Body weight, SAPS II and APACHE II are expressed as mean ± standard deviation. All other continuous variables are expressed as
median (IQR)
446Injury in 17 (5.6%) and Failure in 24 (8.0%). Progression
of AKI to a worse RIFLE class was seen in 37 patients
(28% of AKI patients). The maximum RIFLE class
reached (RIFLE-max) was Risk in 57 patients (18.9%),
Injury in 42 (14%) and Failure in 34 (11.3%). Fifteen
patients (5%) were treated with RRT in the ICU. AKI
patients were older, less likely to have a neurologic
diagnosis and more likely to have a respiratory diagnosis
on ICU admission, had higher APACHE II, SAPS II and
SOFAscores,andhigherbaselineandadmissionSCrvalues.
They were more likely to have had exposure to potential
nephrotoxins prior to their ICU admission, and to have
received diuretics during their ICU stay. Sixty-six AKI
patients (49.6%) fulﬁlled criteria for sepsis during their
ICU stay, compared to 49 (29.2%) of non-AKI patients
(P\0.001), whereas 83 AKI patients (62.4%) fulﬁlled
criteriaforSIRSorsepsisduringtheirICUstay,ascompared
to 80 (47.6%) of non-AKI patients (P = 0.014).
AKI patients had a higher crude ICU mortality (27.8%
vs. non-AKI 8.9%, P\0.001) and longer ICU length of
stay [median 9 days vs. 5 days (non-AKI), P\0.001].
Sixty-four patients (48% of AKI patients) had complete
recovery of renal function, with a SCr at time of ICU
discharge that was \150% of baseline; an additional 27
AKI patients (20%) had partial renal recovery.
NGAL in AKI and non-AKI
The median ﬁrst pNGAL in the study population was
117.0 (IQR 68.2, 213.8) ng/ml, which was signiﬁcantly
higher than 61.2 (IQR 60.0–78.5) ng/ml observed in
apparently healthy adults (P\0.001). Even ICU patients
without AKI had signiﬁcantly higher pNGAL levels
(82.0 ng/ml, IQR 49.7, 134.1) compared to healthy adults
(P = 0.004). A summary of ﬁrst pNGAL values in the
study population is shown in Fig. 1. Compared to non-
AKI patients, pNGAL values were higher among patients
who already had AKI at the time of ﬁrst pNGAL mea-
surement (213.7 ng/ml, IQR 110.4, 553.3; P\0.001 vs.
non-AKI), as well as in patients who developed AKI
within 48 h (209.0 ng/ml, IQR 101.4, 268.2; P\0.001
vs. non-AKI). Patients who developed AKI within 24 h
had a median pNGAL of 225.3 ng/ml (IQR 163.0, 279.5;
P\0.001 vs. non-AKI), whereas those who developed it
within 24–48 h had a median pNGAL of 140.7 ng/ml
(IQR 95.8, 218.3; P = 0.13 vs. non-AKI). In contrast,
patients who developed AKI after [48 h had pNGAL
similar to non-AKI patients (79.8 ng/ml, IQR 52, 143.9;
P = 0.81). The proportion of AKI patients was higher
with progressive quartiles of ﬁrst pNGAL measurement
(see ESM ﬁle 1, ESM Fig. 1, P\0.001).
A graphical representation of the kinetics of pNGAL is
shown in Fig. 2. For AKI patients, the X-axis shows AKI
Day [4, 8]. AKI Day 0 is the day in which the diagnosis of
AKI was made based on the RIFLE criteria. One day prior
to AKI, pNGAL was higher in these patients compared to
non-AKI, and increased further on AKI Day 0. Patients
who never developed AKI had comparatively lower
pNGAL values without notable variation during the study
period (P\0.001 at each time point).
NGAL and prediction of clinical outcome
Performance characteristics of pNGAL for prediction of
AKI and secondary outcomes are shown in Fig. 3 and
Table 2. Plasma NGAL was a good diagnostic marker for
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447AKI development within the next 48 h from the ﬁrst
measurement (Fig. 3), with an area under ROC (AuROC)
of 0.78 (95% CI 0.65–0.90). Using a threshold value of
150 ng/ml for pNGAL, the sensitivity was 73%, and
speciﬁcity was 81% (Table 2). Plasma NGAL lev-
els[150 ng/ml were associated with increased odds of
AKI of 11.8 (95% CI 3.5–39.2). Furthermore, pNGAL
was also a good predictor for RRT use during the ICU
stay (AuROC 0.82, 95% CI 0.70–0.95). However, its
performance was comparatively weaker with regards to
prediction of AKI occurring within the next 5 days, ICU
mortality, and the composite endpoint of RRT and ICU
mortality (AuROC 0.67, 0.67 and 0.68, respectively).
We also described the cohort with respect to the ascer-
tained threshold pNGAL value (see ESM File 1, ESM
Table 2). The ﬁndings are similar to Table 1, reﬂecting the
association between AKI and elevated pNGAL levels.
Patients with ﬁrst pNGAL [150 ng/ml were older, were
more likely to have CKD, have higher APACHE II and
SOFA scores and SCr on ICU admission, and were more
likely to have had exposure to potential nephrotoxins. Over
70% of these patients had AKI during their ICU stay. Also,
this group had higher RRT use (11.7%) and ICU mortality
(27%). The duration of AKI among survivors was longer in
patientswithﬁrstpNGAL[150 ng/mlversusthosewithﬁrst
pNGAL\150 ng/ml (4 days, IQR 2,7 vs. 2 days, IQR 1,6,
respectively, P = 0.013).
NGAL and severity of illness and AKI
All blood specimens were used to calculate peak and
mean pNGAL values [4]. Peak pNGAL concentrations
increased with worsening severity of AKI (Table 3).
There was a similar relationship between mean pNGAL
levels and RIFLE-max class (Non-AKI 71.4 ng/ml, IQR
43.9, 124.3; Risk 139.9 ng/ml, IQR 67.4, 185.0; Injury
161.6 ng/ml, IQR106.9–286.1; Failure 522.0 ng/ml, IQR
288.2–1061.8; P\0.001 by Kruskal–Wallis test). Peak
pNGAL levels also correlated well with RIFLE-max class
(R = 0.554, P\0.001). Patients were further grouped
according to APACHE II, SAPS II and SOFA scores, and
by presence of sepsis. In general, pNGAL levels were
higher among patients with higher severity of illness
scores, whether expressed as peak pNGAL (Table 3),
mean pNGAL or ﬁrst pNGAL levels (data not shown).
There were weak but highly statistically signiﬁcant cor-
relations between peak NGAL levels and APACHE II
(R = 0.287, P\0.001), SAPS II (R = 0.215, P\0.001)
and SOFA scores (R = 0.289, P\0.001). There was no
signiﬁcant difference in pNGAL among patients with and
without sepsis or SIRS (Table 3).
Table 4 shows the results of posthoc univariate and
multivariate logistic regression analysis using age,
APACHE II scores and ﬁrst pNGAL concentration as
independent variables to predict AKI within 48 h of
admission. Age was not signiﬁcant in either the univariate
or multivariate model, whereas APACHE II was mar-
ginally signiﬁcant, and NGAL was highly signiﬁcant. The
adjusted odds ratio for pNGAL did not depend signiﬁ-
cantly on which ICU severity score was used (APACHE
II, SAPS II or SOFA) in the model; the best model was
that using the APACHE II.
Discussion
We conducted a prospective study to evaluate plasma
NGAL for the early diagnosis of AKI in a heterogeneous
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the next 48 h
Table 2 Test characteristics of plasma NGAL for acute kidney injury and clinical outcomes
ROC analysis At cutoff of 150 ng/ml
AuC ROC (95% CI) Sensitivity (95% CI) Speciﬁcity (95% CI) PPV (95% CI) NPV (95% CI)
AKI within 48 h 0.78 (0.65–0.90) 0.73 (0.45–0.92) 0.81 (0.75–0.86) 0.24 (0.13–0.39) 0.97 (0.93–0.99)
AKI within 5 days 0.67 (0.55–0.79) 0.46 (0.27–0.67) 0.80 (0.74–0.86) 0.26 (0.14–0.41) 0.91 (0.85–0.95)
RRT within ICU stay 0.82 (0.70–0.95) 0.87 (0.60–0.98) 0.65 (0.60–0.71) 0.12 (0.06–0.19) 0.99 (0.96–1.00)
ICU mortality 0.67 (0.58–0.77) 0.60 (0.45–0.73) 0.68 (0.61–0.73) 0.28 (0.20–0.37) 0.89 (0.84–0.93)
RRT ? ICU mortality 0.68 (0.59–0.77) 0.60 (0.47–0.73) 0.68 (0.62–0.74) 0.31 (0.23–0.41) 0.88 (0.82–0.92)
448adult population. The key ﬁndings of this study are the
following: ﬁrst, 44% of ICU patients had AKI during their
ICU stay, and nearly 30% had this within 24 h of
admission, consistent with prior studies [9]. Second,
plasma NGAL levels are signiﬁcantly higher in ICU
patients compared to healthy adults and are higher in AKI
patients compared to non-AKI patients. Third, pNGAL
was a good independent predictor for the development of
AKI within the next 48 h (AuROC 0.78, 95% CI 0.65–
0.90) and for RRT use during the ICU stay (AuROC 0.82,
95% CI 0.70–0.95). Fourth, pNGAL correlated with
severity of AKI, as well of severity of illness.
Human NGAL is a 25-kDa protein covalently bound to
gelatinaseandisoneofthemostupregulatedtranscriptsinthe
kidney very early after acute injury [1]. To our knowledge,
thisprospectivestudyistheﬁrsttoexamineplasmaNGALin
aheterogeneousadultpopulation.TheAuROCinourstudyis
highly consistent with that reported in 19 studies across dif-
ferent AKI settings (Haase et al., AJKD 2009, in press), but
slightly lower than that reported in pediatric studies [10–12].
This is related to multiple factors, including the presence of
co-morbidconditionsandunderlyingchronickidneydisease
(CKD) in our adult ICU population compared to children.
These conditions may lead to elevation of NGAL levels
independent of renal injury, which could confound the pre-
dictiveabilityofpNGALforAKI[13–15].Moreover,unlike
surgery or radiocontrast exposure, neither the timing nor
severity of the renal insult is known in a general ICU. In the
setting of cardiopulmonary bypass, for example, there is a
temporally predictable injury to the kidneys, and surrogate
markersoftheseverityofinjurysuchascross-clamptimeare
available. In contrast nephropathy, the amount of adminis-
teredradiocontrastmaybeasurrogateforthedegreeofrenal
injury. In comparison, although pNGAL could be measured
in critically ill patients within the ﬁrst 24 h of admission to
the ICU, this may not necessarily be the ﬁrst 24 h of their
diseaseprocess.Furthermore,inthemedicalICU,thekidney
is likely to receive ‘‘multiple hits’’ of varying severity, quite
differentfromtheseemingly‘‘singlehit’’modelencountered
in most surgical situations.
Both serum and urine NGALs (uNGAL) have been
studied as markers for AKI in critically ill pediatric
patients. Serum NGAL was a highly sensitive but non-
speciﬁc predictor of AKI in children with septic shock
(AuROC 0.68) [5]. In a heterogeneous pediatric ICU
population, uNGAL was a useful early marker for devel-
opment of AKI within 48 h, with AuROC 0.78 [4]. Similar
toourownﬁndings,meanandpeakuNGALincreasedwith
worse pediatric RIFLE class. They also observed a weak
correlation between Pediatric Risk of Mortality (PRISM)
scores and mean and peak uNGAL in AKI patients.
In adults, Makris et al. found uNGAL measured within
24 h from injury to be a useful early AKI marker in
critically ill trauma patients, with AuROC of 0.97 [2].
This situation is analogous to that of surgery or contrast
nephropathy, where the timing of renal insult is clearly
deﬁned. In addition, the AKI group was signiﬁcantly
older than the non-AKI group (median age 60 vs. 32
years, respectively), and this may have contributed to the
relatively high AuROC in this study. In a recent single-
center study in critically ill adults, uNGAL was shown to
have moderate predictive utility for the development of
AKI, although its additional contribution to conventional
clinical risk factors appears limited [16].
Table 3 Peak plasma NGAL values by patient subgroups
Category Mean ± SD Median (IQR) P
RIFLE-max
NonAKI 162.1 ± 302.8 102.4 (67.4, 147.5) \0.001
Risk 229.6 ± 199.4 171.4 (101.9, 281.7)
Injury 332.4 ± 314.2 214.9 (137.5, 419.5)
Failure 803.8 ± 529.2 620.3 (406.4, 1366.4)
APACHE II
BMedian 219.0 ± 361.0 117.4 (77.9, 193.9) \0.001
[Median 329.8 ± 387.8 173.0 (89.4, 407.8)
SAPS II
BMedian 223.1 ± 354.7 123.4 (76.0, 224.8) 0.005
[Median 322.8 ± 395.1 152.8 (90.2, 395.4)
SOFA
BMedian 248.1 ± 390.5 120.9 (77.0, 214.8) 0.001
[Median 310.5 ± 352.1 175.2 (100.4, 401.9)
Sepsis
No 264.9 ± 394.0 133.2 (80.0, 244.4) 0.334
Yes 281.2 ± 350.2 137.5 (86.6, 373.8)
Sepsis or SIRS
No 265.6 ± 335.7 140.9 (82.1, 255.0) 0.717
Yes 275.8 ± 410.3 132.2 (79.2, 283.3)
Median APACHE II score = 18
Median SAPS II score = 40
Median SOFA score = 5
Table 4 Univariate and multivariate analysis of plasma NGAL for prediction of acute kidney injury (AKI) within 48 h
Univariate Multivariate
OR (95%CI) P OR (95%CI) P
Age 1.003 (0.977–1.030) 0.832 0.987 (0.959–1.015) 0.360
APACHE II 1.074 (0.999–1.154) 0.052 1.084 (1.000–1.174) 0.050
log (pNGAL) 4.989 (1.496–5.652) 0.002 3.059 (1.509–6.201) 0.002
The odds ratio for each independent variable is a point estimate
computed from the model coefﬁcient (beta). The adjusted odds
ratio for pNGAL did not depend signiﬁcantly on which ICU
severity score was used (APACHE II, SAPS II or SOFA) in the
model; the best model was that using the APACHE II
449Ourstudymakesanimportantcontributiontothecurrent
body of literature on NGAL and AKI. Ours is the ﬁrst study
to prospectively evaluate plasma NGAL in all patients
admitted to an adult general ICU, making the results more
readily applicable to the usual ICU population. The cohort
was followed through the entire ICU stay. This study also
utilizes both the SCr and urine output criteria of RIFLE, as
recommendedbythe ADQI group [6]. Moreover, we useda
standardized user-friendly platform; a recent meta-analysis
reported better AuROCs with standardized NGAL assays
compared to ‘‘research-based’’ ELISA assays (Haase et al.,
AJKD 2009, in press). Our use of a commercially available
platform is also a potential strength, since this would allow
other investigators to conﬁrm these ﬁndings. Our results
show that pNGAL is a useful biomarker even in a popula-
tion with common co-morbidities, such as diabetes, CKD
and exposure to potential nephrotoxins. As such, it com-
plements the original study that recruited a homogenous
cohort of children who had no co-morbidities and had
normal renal function [10]. Finally, we demonstrate inadult
ICU patients that pNGAL correlates with severity of AKI
and critical illness, yet remains an independentpredictor for
AKI after adjustment for severity of illness. Other investi-
gators have looked at other novel biomarkers for AKI in
critically ill adults, including cystatin-C [17], IL-18 [8],
IL-6 [18], soluble TNF-receptors (S-TNF-R) [19], urinary
N-acetyl-b-(D)-glucominidase activity (NAG) [20, 21],
kidney injury molecule-1 (KIM-1) [20, 21] and matrix
metalloproteinase-9 (MMP-9) [21]. Some of these studies
looked at either selected high-risk ICU populations [17]o r
enrollees in randomized controlled trials [8, 18, 19]; there-
fore, the results may not be broadly applicable to the more
general population seen in clinical practice.
We acknowledge certain limitations in this study. This
study enrolled patients from a single center; data from a
multicenter study would be more generalizable. Moreover,
nearly 30% of patients in this study already fulﬁlled cri-
teria for AKI on admission to the ICU. This is consistent
with data froma large observational studythat showed that
AKI occurred in 36% on the day of ICU admission [9].
This may be an important limitation for any studies on
early biomarkers in an unselected adult ICU population.
In summary, plasma NGAL appears to be a useful
early marker for the development of AKI in a large het-
erogeneous adult ICU population, allowing the diagnosis
of AKI up to 48 h prior to a clinical diagnosis based on
AKI consensus deﬁnitions. It is also a good predictor of
need for RRT, and correlates with AKI severity and
overall severity of illness. Early identiﬁcation of patients
who are likely to develop AKI and those who may require
RRT will allow early targeted therapy of these high risk
patients with potentially beneﬁcial treatments before
signiﬁcant renal injury occurs.
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